Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

The year 2013 was strong for Shire (SHPG - Analyst Report). The company repositioned its business in 2013 undertaking a realignment program with strategic focus on rare diseases and greater operational discipline.

Shire recently updated its guidance for 2013 at the JP Morgan Healthcare Conference. The company now expects to report earnings at the upper end of the mid-to-high teens guidance range provided earlier with the  third quarter results.

In a bid to strengthen its portfolio of rare disease drugs, Shire announced that it will acquire ViroPharma Inc. for approximately $50 per share or $4.2 billion in Nov 2013.

Shire remains confident, that if the potential acquisition goes through, will augment both its top line and bottom line. ViroPharma's lead drug Cinryze is approved in the U.S. for routine prophylaxis against angioedema attacks in adolescent and adults with hereditary angioedema  (HAE). Cinryze complements Shire's Firazyr which is indicated for the on-demand treatment of acute HAE attacks. The potential acquisition is expected to generate synergies over $150 million in 2015.

Meanwhile, Shire’s expects data from various studies on its key pipeline candidates in 2014 – attention deficit and hyperactivity disorder (ADHD) drug Vyvanse for major depressive disorder, data from dry eye disease candidate lifitegrast, label expansion of Xagrid (essential thrombocythemia), data on ADHD drug Intuniv among others.

With an aim to reduce overlap, Shire has merged its three autonomous divisions into one. Shire has decided to pursue development programs with a focus on rare diseases only. Hence, it discontinued all other development programs. We believe Shire’s efforts to build a leaner organization with better focus on rare diseases should lead to improved margins.

Shire carries a Zacks Rank #3 (Hold). Investors may consider companies like Forest Laboratories (FRX - Analyst Report) and Questcor Pharmaceuticals Inc. (QCOR - Analyst Report), which carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%